• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Diabetes

The 11 most innovative medical devices of 2017

October 19, 2017 By Danielle Kirsh

The nominees for the best medical technology of 2017 were recently announced for the 11th Annual Prix Galien USA Awards. The Galien Foundation, the host of the awards, hands out the Prix Galien Award annually to examples of outstanding biomedical and technology product achievement designed to improve human condition. Before candidates can qualify for the […]

Filed Under: Cardiovascular, Diabetes, Diagnostics, Featured, Hematology, Hospital Care, Imaging, Neurological, Oncology, Patient Monitoring, Research & Development, Surgical, Wound Care Tagged With: abbott, Allergan, Biosense Webster, Boston Scientific, BrainScope, DePuy Synthes, Ethicon, INSIGHTEC, Integra LifeSciences, johnsonandjohnson, Koning Corporation, medtech

Insulet, Dexcom partner to lure ex-Animas users

October 19, 2017 By Brad Perriello

Insulet (NSDQ:PODD) and Dexcom (NSDQ:DXCM) yesterday floated a joint promotion aimed at luring users of the Animas insulin pump after Johnson & Johnson (NYSE:JNJ) bails out of the insulin pump biz. The companies are hoping to chip off a piece of the diabetes market from Medtronic (NYSE:MDT), to which J&J has offered to help some 90,000 Animas patients transfer (J&J is also evaluating another […]

Filed Under: Diabetes, Featured, Wall Street Beat Tagged With: DexCom Inc., Insulet

FDA committee backs Novo Nordisk’s once-weekly type II diabetes drug

October 18, 2017 By Sarah Faulkner

Novo Nordisk

An FDA advisory committee has voted favorably to approve Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide Type II diabetes drug. Shares in the insulin maker were up 2% in after-hours activity today, trading at $50.13 apiece. While one member of the FDA’s endocrinologic and metabolic drugs advisory committee abstained from voting, the other members voted 16-0 to […]

Filed Under: Clinical Trials, Diabetes, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Novo Nordisk

DarioHealth wins CE Mark for glucose meter that connects to iPhone 7, 8 devices

October 18, 2017 By Sarah Faulkner

DarioHealth

DarioHealth (NSDQ:DRIO) said today that it won CE Mark approval for the version of its Dario blood glucose monitoring system that fits with the Lightning connector on Apple’s iPhone 7 and iPhone 8 smart phones. With this regulatory win, DarioHealth’s smart glucose meter can be used with a 3.5 mm headphone jack or Lightning connector, the […]

Filed Under: Diabetes, Featured, Regulatory/Compliance, Wall Street Beat Tagged With: dariohealth

OptiScan’s glucose monitoring system for the ICU wins 510(k) clearance

October 18, 2017 By Sarah Faulkner

OptiScan

OptiScan Biomedical said today that its OptiScanner 5000 glucose monitoring system won 510(k) clearance. The device is the first of its kind, providing physicians with trending and tracking information to manage their patients’ blood glucose levels in surgical intensive care units. The Hayward, Calif.-based company’s technology uses alarms to alert clinicians when patients are experiencing […]

Filed Under: Diabetes, Featured, Food & Drug Administration (FDA), Hospital Care, Regulatory/Compliance Tagged With: optiscanbiomedical

Adventist Health System to use Glytec’s diabetes management system at 39 acute care facilities

October 17, 2017 By Sarah Faulkner

Adventist Health System, Glytec collaboration

Glytec has partnered with Adventist Health System to bring its eGlycemic diabetes management system to 39 of the health system’s acute care facilities. Glytec’s cloud-based eGMS will become a part of the standard of care for patients who need insulin therapy, in both the critical care units and on the medical-surgical floor, the companies said. […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Hospital Care, Pharmaceuticals Tagged With: Glytec

Researchers combine a smart phone, insulin pump and CGM in diabetes study

October 17, 2017 By Sarah Faulkner

diabetes

In a study published this week in Diabetes Care, researchers combined an insulin pump, a continuous glucose monitoring receiver and a smart phone with cloud-based algorithms to automatically monitor and adjust a patient’s glucose levels. The team pointed towards a number of systems that are designed to function as an artificial pancreas, but still require that […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Harvard University

Insulet shareholder sues over OmniPod Eros

October 16, 2017 By Sarah Faulkner

Insulet Omnipod

Insulet (NSDQ:PODD) shareholder Frank Carnazza filed a derivative suit against the Billerica, Mass-based company last week in a Massachusetts federal court, alleging that Insulet misrepresented the success of its OmniPod Eros roll-out in 2013, which eventually caused the shares in the company to plummet. Carnazza named a number of former and current executives in the suit, […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Insulet

Tandem prices $16m public offering

October 13, 2017 By Sarah Faulkner

Tandem Diabetes

Tandem Diabetes Care (NSDQ:TNDM) today priced an underwritten public offering of 4,630,000 shares of its common stock, Series A warrants and Series B warrants to buy 4,630,000 shares of common stock at $3.50 apiece. The San Diego, Calif.-based company said it expects to bring in $16.2 million in gross proceeds from the offering. The offering’s Series […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Tandem Diabetes Care

Here’s how the diabetes industry’s leaders think about patient-centered R&D

October 11, 2017 By Sarah Faulkner

diabetes

Designing devices centered around patients is a goal espoused by nearly all device companies nowadays, as they aim to make products that people want to use and can incorporate into their everyday lives. Underscoring those products is often years of research and some in the industry have begun to think about how a patient’s needs […]

Filed Under: Clinical Trials, Diabetes, Featured, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: Bigfoot Biomedical, drugstars, Eli Lilly & Co., Novo Nordisk

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 153
  • Page 154
  • Page 155
  • Page 156
  • Page 157
  • Interim pages omitted …
  • Page 177
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS